AN2 Therapeutics Inc (ANTX)
2.55
+0.02
(+0.79%)
USD |
NASDAQ |
May 03, 16:00
2.55
0.00 (0.00%)
After-Hours: 20:00
AN2 Therapeutics Free Cash Flow (Quarterly): -17.07M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -17.07M |
| September 30, 2023 | -11.80M |
| June 30, 2023 | -12.82M |
| March 31, 2023 | -11.60M |
| December 31, 2022 | -7.638M |
| September 30, 2022 | -9.487M |
| Date | Value |
|---|---|
| June 30, 2022 | -9.595M |
| March 31, 2022 | -6.742M |
| December 31, 2021 | -8.993M |
| September 30, 2021 | -4.691M |
| June 30, 2021 | -5.257M |
| March 31, 2021 | -1.543M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-17.07M
Minimum
Dec 2023
-1.543M
Maximum
Mar 2021
-8.936M
Average
-9.24M
Median
Free Cash Flow (Quarterly) Benchmarks
| Gilead Sciences Inc | 2.219B |
| QuidelOrtho Corp | 31.80M |
| CymaBay Therapeutics Inc (DELISTED) | -27.56M |
| Insmed Inc | -132.97M |
| Revance Therapeutics Inc | -44.51M |